The Death of CNS Drug Development: Overstatement or Omen?

Dec 2011 -

Neal R. Cutler M.D., Henry J. Riordan Ph.D.

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Jun 2004 -

Sridhar K. Rabindran, Carolyn M. Discafani, Edward C. Rosfjord, Michelle Baxter, M. Brawner Floyd, Jonathan Golas, William A. Hallett, Bernard D. Johnson, Ramaswamy Nilakantan, Elsebe Overbeek, Marvin F. Reich, Ru Shen,1 Xiaoqing Shi, Hwei-Ru Tsou, Yu-Fen

The Alzhiemer's Association external quality control program for cerebrospinal fluid biomarkers

Jan 2011 -

Cutler, Nowatzke

Recommendations on: internal standard criteria, stability, incurred sample reanalysis and recent 483s by the Global CRO Council for Bioanalysis

Jan 2011 -

Lowes, Michele Malone

Systematic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development

Jan 2010 -

Nowatzke, Cole, Bowsher

Unique challenges of providing bioanalytical support for biological theapeutic pharmacokinetic programs

Jan 2011 -

Nowatzke, Rogers, Wells, Bowsher, Ray, Unger

Quantitative Determination and Validation of Serotonin (5-HT) in Human CSF

Jan 2010 -

Espinosa